Aliases & Classifications for Osteonecrosis

Summaries for Osteonecrosis

MedlinePlus : 40 Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as bone necrosis, is related to osteonecrosis of the jaw and thrombophilia, and has symptoms including sciatica, muscle cramp and back pain. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Rheumatoid arthritis and Statin Pathway - Generalized, Pharmacokinetics. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 An ischemic bone disease that results_in necrosis located in bone.

Wikipedia : 72 death of bone tissue due to interruption of the blood... more...

Related Diseases for Osteonecrosis

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis of the jaw 33.4 CYP2C8 FDPS VEGFA
2 thrombophilia 30.3 F2 MTHFR SERPINC1 SERPINE1
3 myeloma, multiple 30.0 ABCB1 TNFRSF11B TNFSF11 VEGFA
4 disseminated intravascular coagulation 30.0 F2 SERPINC1 SERPINE1
5 osteoporotic fracture 30.0 MTHFR TNFRSF11B
6 periodontitis 30.0 BGLAP TNFRSF11B TNFSF11
7 protein s deficiency 30.0 F2 MTHFR SERPINC1
8 osteomyelitis 29.9 ACP5 BMP2 TNFSF11
9 kummell's disease 29.9 TNFRSF11B TNFSF11
10 renal osteodystrophy 29.8 BGLAP PTH TNFRSF11B
11 pseudoarthrosis 29.8 BMP2 PTH
12 antithrombin iii deficiency 29.8 F2 MTHFR SERPINC1
13 cohen-gibson syndrome 29.7 BGLAP TNFRSF11B TNFSF11
14 protein c deficiency 29.7 F2 MTHFR SERPINC1
15 villonodular synovitis 29.7 ACP5 TNFSF11
16 legg-calve-perthes disease 29.6 COL2A1 SERPINC1 SERPINE1
17 giant cell tumor 29.4 BGLAP TNFRSF11B TNFSF11
18 vascular disease 29.1 MTHFR SERPINC1 SERPINE1 TNFRSF11B VEGFA
19 paget's disease of bone 28.3 ACP5 BGLAP PTH TNFRSF11B TNFSF11
20 glucocorticoid-induced osteoporosis 27.4 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
21 osteoporosis 26.6 ACP5 BGLAP BMP2 COL2A1 CYP3A4 FDPS
22 dysbaric osteonecrosis 12.3
23 avascular necrosis of femoral head, primary, 1 11.6
24 familial avascular necrosis of the femoral head 11.4
25 freiberg's disease 11.2
26 thiemann disease 10.9
27 kienbock's disease 10.9
28 inferior vena cava interruption 10.6 MTHFR SERPINE1
29 neonatal stroke 10.6 MTHFR SERPINE1
30 amaurosis fugax 10.6 MTHFR SERPINE1
31 hemifacial spasm 10.5 MTHFR VEGFA
32 mesenteric vascular occlusion 10.5 F2 MTHFR
33 livedoid vasculopathy 10.5 F2 MTHFR SERPINE1
34 cryptogenic cirrhosis 10.5 F2 MTHFR SERPINE1
35 buerger disease 10.4 F2 MTHFR SERPINE1
36 fibrinolytic defect 10.4 SERPINC1 SERPINE1
37 koro 10.4 ABCB1 CYP3A4
38 mucositis 10.4 ABCB1 MTHFR VEGFA
39 intestinal impaction 10.4 F2 SERPINC1
40 fournier gangrene 10.4 F2 SERPINC1
41 spinal cord infarction 10.3 F2 MTHFR SERPINC1
42 sudden sensorineural hearing loss 10.3 F2 MTHFR SERPINC1
43 blood protein disease 10.3 F2 MTHFR SERPINC1
44 argentine hemorrhagic fever 10.3 SERPINC1 SERPINE1
45 axial osteomalacia 10.3 BGLAP PTH
46 polyarticular onset juvenile idiopathic arthritis 10.3 TNFRSF11B TNFSF11
47 marantic endocarditis 10.3 F2 MTHFR SERPINC1
48 hemangioma of liver 10.3 CYP3A4 F2
49 blue toe syndrome 10.3 F2 SERPINC1 SERPINE1
50 hepatic infarction 10.3 F2 MTHFR SERPINC1

Graphical network of the top 20 diseases related to Osteonecrosis:



Diseases related to Osteonecrosis

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:


sciatica, muscle cramp, back pain

MGI Mouse Phenotypes related to Osteonecrosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 BMP2 PTH COL2A1 RUNX2 F2 ABCB1
2 growth/size/body region MP:0005378 10.17 MTHFR BMP2 PTH COL2A1 RUNX2 F2
3 homeostasis/metabolism MP:0005376 10.11 MTHFR BMP2 PTH COL2A1 F2 ABCB1
4 hematopoietic system MP:0005397 10.1 BMP2 PTH RUNX2 F2 ABCB1 VEGFA
5 immune system MP:0005387 10.06 BMP2 PTH COL2A1 RUNX2 F2 ABCB1
6 craniofacial MP:0005382 10 BMP2 PTH COL2A1 RUNX2 TNFRSF11B TNFSF11
7 mortality/aging MP:0010768 9.93 BMP2 PTH COL2A1 RUNX2 F2 ABCB1
8 limbs/digits/tail MP:0005371 9.86 BMP2 PTH COL2A1 RUNX2 MTHFR TNFRSF11B
9 reproductive system MP:0005389 9.56 MTHFR BMP2 F2 ABCB1 VEGFA RUNX2
10 skeleton MP:0005390 9.28 BMP2 PTH COL2A1 RUNX2 F2 MTHFR

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 1 121268-17-5, 66376-36-1 2088
2
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
3
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
4
Dalteparin Approved Phase 4 9005-49-6
5
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
6
Rivaroxaban Approved Phase 4 366789-02-8
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
8
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
9 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
11 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1
13 glucocorticoids Phase 4,Phase 3,Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
17 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1
18 Anticoagulants Phase 4
19 Antithrombin III Phase 4
20 Antithrombins Phase 4
21 calcium heparin Phase 4
22 Factor Xa Inhibitors Phase 4
23 Heparin, Low-Molecular-Weight Phase 4
24 HIV Protease Inhibitors Phase 4
25
protease inhibitors Phase 4
26 Serine Proteinase Inhibitors Phase 4
27 Pharmaceutical Solutions Phase 4
28 Protective Agents Phase 4,Phase 3
29 Micronutrients Phase 4,Phase 3,Phase 2
30 Trace Elements Phase 4,Phase 3,Phase 2
31 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
32 Ferrosoferric Oxide Phase 4
33 Hematinics Phase 4
34 Parenteral Nutrition Solutions Phase 4
35 Adjuvants, Immunologic Phase 4
36 Viscosupplements Phase 4
37 Platelet Aggregation Inhibitors Phase 4,Phase 3
38 Tocopherols Phase 4,Phase 3
39 Tocotrienols Phase 4,Phase 3
40 Antioxidants Phase 4,Phase 3
41 Phosphodiesterase Inhibitors Phase 4,Phase 3
42 Radiation-Protective Agents Phase 4,Phase 3
43 Vasodilator Agents Phase 4,Phase 3
44 serine Nutraceutical Phase 4
45 Tocotrienol Investigational, Nutraceutical Phase 4,Phase 3 6829-55-6
46
Gemcitabine Approved Phase 3 95058-81-4 60750
47
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
48
Denosumab Approved Phase 3,Phase 1 615258-40-7
49
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
50
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 162)

# Name Status NCT ID Phase Drugs
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
2 Vertebral Fracture and Osteonecrosis Associated With High-dose Glucocorticoid Completed NCT00679978 Phase 4
3 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
4 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings Completed NCT01806766 Phase 4
5 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
6 Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
7 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
8 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4 Rivaroxaban;Enoxaparin
9 Benefit of Orthopedic Navigation in the ARThroplasty of the Hip Completed NCT01496300 Phase 4
10 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4 Ferumoxytol-enhanced magnetic resonance imaging
11 Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis Recruiting NCT02984228 Phase 4 Hyaluronic Acid
12 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
13 Management of Mandibular ORN: PENTO as Medical Treatment Active, not recruiting NCT02368457 Phase 4 Pentoxifylline and Tocopherol
14 Optetrak Posterior Stabilized Versus Optetrak Hi-Flex Withdrawn NCT00808613 Phase 4
15 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
16 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3 Ibandronate IV;Placebo
17 Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3 zoledronic acid (aclasta)
18 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
19 Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip Recruiting NCT03405974 Phase 3 Aspirin;Placebo
20 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Recruiting NCT01529008 Phase 3 Core decompression/PREOB® implantation;Core decompression/placebo implantation
21 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3 cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
22 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
23 Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head Active, not recruiting NCT01892514 Phase 3
24 ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee Active, not recruiting NCT01458782 Phase 2, Phase 3
25 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3 zoledronic acid
26 Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease Enrolling by invitation NCT02536755 Phase 3 eliglustat GZ385660
27 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw Not yet recruiting NCT03390777 Phase 2, Phase 3
28 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Not yet recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
29 Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Terminated NCT02114489 Phase 3 ibandronate;Placebo
30 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
31 A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement Terminated NCT00208468 Phase 3
32 Osteonecrosis of the Hip and Bisphosphonate Treatment Unknown status NCT00781261 Phase 2 Zoledronic Acid;Placebo
33 MBCP Safety and Performance in the Osteonecrosis of Femur Head Unknown status NCT00289575 Phase 2
34 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 2
35 PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells Completed NCT01700920 Phase 2
36 Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Completed NCT02890537 Phase 2 Core decompression/PREOB® implantation;Core decompression/BMC implantation
37 Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty Completed NCT01622465 Phase 2
38 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed NCT00921557 Phase 2 Alendronate;Placebo
39 Shock Wave Therapy for Osteoporosis Completed NCT02630381 Phase 2
40 Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery Completed NCT00393848 Phase 2 Essential amino acid supplement;Ketoconazole;Placebo
41 Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study Recruiting NCT02632903 Phase 2 Zoledronic acid
42 Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease Active, not recruiting NCT02448121 Phase 1, Phase 2
43 Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head Active, not recruiting NCT01605383 Phase 1, Phase 2
44 Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip Active, not recruiting NCT02065167 Phase 2
45 The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells Not yet recruiting NCT03180463 Phase 1, Phase 2 Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
46 Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus Terminated NCT00412841 Phase 2 Atorvastatin;Placebo
47 Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee Withdrawn NCT00477217 Phase 2 Zoledronic acid
48 Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee Unknown status NCT01950858 Phase 1
49 Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head Completed NCT01198080 Phase 1
50 Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation Completed NCT00821470 Phase 1

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC
PREOB
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Genetic Tests for Osteonecrosis

Anatomical Context for Osteonecrosis

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

18
Bone

MalaCards organs/tissues related to Osteonecrosis:

38
Bone, Bone Marrow, Testes, Skin, Endothelial, Breast, Prostate

Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 1026)
# Title Authors Year
1
Thrombophilia-Associated Factors in Patients with Spontaneous Osteonecrosis of the Knee. ( 29308659 )
2018
2
Enhanced bone defect repairing effects in glucocorticoid-induced osteonecrosis of the femoral head using a porous nano-lithium-hydroxyapatite/gelatin microsphere/erythropoietin composite scaffold. ( 29369309 )
2018
3
Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review. ( 29225245 )
2018
4
FGF2 and FAM201A affect the development of osteonecrosis of the femoral head after femoral neck fracture. ( 29382571 )
2018
5
Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. ( 29362430 )
2018
6
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. ( 29365278 )
2018
7
Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw. ( 29224060 )
2018
8
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )
2018
9
High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. ( 29394948 )
2018
10
Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw. ( 29249520 )
2018
11
Interferon I^ protects against avascular osteonecrosis through interleukin 6 inhibition and silent information regulator transcript-1 upregulation. ( 29423066 )
2018
12
Articular reconstruction of the humeral head with autogenous allograft in the treatment of the osteonecrosis. ( 29367916 )
2018
13
Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study. ( 29435826 )
2018
14
Short stem survival after osteonecrosis of the femoral head. ( 29396635 )
2018
15
Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment. ( 29412504 )
2018
16
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
17
Association of common comorbidities with osteonecrosis: a nationwide population-based case-control study in Denmark. ( 29439082 )
2018
18
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )
2018
19
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )
2018
20
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )
2018
21
Treatment of displaced femoral neck fractures in young patients with DHS and its association to osteonecrosis. ( 29367911 )
2018
22
Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions. ( 29432652 )
2018
23
Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )
2018
24
Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )
2018
25
The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. ( 29435623 )
2018
26
Platelet-rich plasma has beneficial effects in mice with osteonecrosis of the femoral head by promoting angiogenesis. ( 29434765 )
2018
27
The Pathophysiological Sequence of Glucocorticoid-induced Osteonecrosis of the Femoral Head in Male Mice. ( 28938402 )
2017
28
Effect of different doses and durations of teriparatide therapy onA resolution of medication-related osteonecrosis of the jaw: AA randomized, controlled preclinical study in rats. ( 29395991 )
2017
29
In Reply-Bisphosphonates and Osteonecrosis of the Jaw. ( 28688472 )
2017
30
Safety and efficacy of hydroxyapatite scaffold in the prevention of jaw osteonecrosis in vivo. ( 28902456 )
2017
31
The timing of bone SPECT to predict osteonecrosis after internal fixation of femur neck fractures. ( 28089085 )
2017
32
Analysis of damage in relation to different classifications of pre-collapse osteonecrosis of the femoral head. ( 28875741 )
2017
33
Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report. ( 28671294 )
2017
34
Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis. ( 28948379 )
2017
35
Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. ( 27856150 )
2017
36
An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty. ( 28068972 )
2017
37
Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. ( 27876532 )
2017
38
Hip Osteonecrosis Is Associated with Increased Plasma IL-33 Level. ( 28167850 )
2017
39
Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw. ( 29215447 )
2017
40
Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. ( 28941210 )
2017
41
Diagnostic dilemma between medication-related osteonecrosis and oral squamous cell carcinoma in a mandibular lytic lesion. ( 28851496 )
2017
42
Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics. ( 28809382 )
2017
43
Spontaneous Healing of Clodronate-Related Osteonecrosis of the Jaw. ( 28857991 )
2017
44
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
2017
45
Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. ( 28760314 )
2017
46
Can Autofluorescence Guide Surgeons in the Treatment of Medication-Related Osteonecrosis of the Jaw? A Prospective Feasibility Study. ( 29175416 )
2017
47
The Effectiveness of Free Vascularized Fibular Flaps in Osteonecrosis of the Femoral Head and Neck: A Systematic Review. ( 28092922 )
2017
48
MMP8 polymorphism is associated with susceptibility to osteonecrosis of the femoral head in a Chinese Han population. ( 28423488 )
2017
49
Phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw. ( 29251459 )
2017
50
Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report. ( 28744112 )
2017

Variations for Osteonecrosis

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Pathways for Osteonecrosis

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1 11.7 ACP5 TNFSF11 VEGFA
2
Show member pathways
11.67 ABCB1 CYP2C8 CYP3A4
3
Show member pathways
11.62 ABCB1 CYP2C8 CYP3A4
4 11.54 BGLAP BMP2 COL2A1 PTH RUNX2
5 11.51 ABCB1 SERPINE1 VEGFA
6
Show member pathways
11.48 ABCB1 CYP2C8 CYP3A4
7 11.48 COL2A1 PTH RUNX2 VEGFA
8
Show member pathways
11.42 ABCB1 CYP2C8 CYP3A4
9
Show member pathways
11.39 ABCB1 CYP2C8 CYP3A4
10 11.15 BGLAP PTH RUNX2 TNFSF11
11
Show member pathways
10.96 ABCB1 CYP2C8 CYP3A4
12 10.82 ABCB1 CYP3A4
13 10.81 ACP5 TNFRSF11B TNFSF11
14 10.76 ABCB1 CYP3A4
15 10.76 ABCB1 CYP2C8 CYP3A4
16 10.75 BGLAP F2
17 10.75 BGLAP CYP3A4 PTH RUNX2 TNFRSF11B TNFSF11
18 10.61 ABCB1 CYP2C8 CYP3A4
19 10.54 ABCB1 CYP3A4
20 10.4 BGLAP PTH TNFRSF11B TNFSF11

GO Terms for Osteonecrosis

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 BGLAP BMP2 COL2A1 F2 PTH SERPINC1
2 endoplasmic reticulum lumen GO:0005788 9.46 BGLAP COL2A1 F2 SERPINC1
3 extracellular space GO:0005615 9.32 BGLAP BMP2 COL2A1 F2 PTH SERPINC1

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.79 CYP2C8 CYP3A4 FDPS
2 osteoblast differentiation GO:0001649 9.75 BGLAP BMP2 RUNX2
3 response to drug GO:0042493 9.72 ABCB1 BGLAP MTHFR PTH TNFRSF11B
4 regulation of receptor activity GO:0010469 9.7 BMP2 F2 PTH SERPINE1 TNFRSF11B TNFSF11
5 mammary gland alveolus development GO:0060749 9.62 TNFSF11 VEGFA
6 osteoblast development GO:0002076 9.61 BGLAP RUNX2
7 regulation of osteoclast differentiation GO:0045670 9.59 BGLAP TNFSF11
8 positive regulation of ossification GO:0045778 9.58 BMP2 PTH
9 chondrocyte differentiation GO:0002062 9.58 BMP2 COL2A1 RUNX2
10 response to inorganic substance GO:0010035 9.57 BGLAP TNFRSF11B
11 positive regulation of blood coagulation GO:0030194 9.56 F2 SERPINE1
12 exogenous drug catabolic process GO:0042738 9.55 CYP2C8 CYP3A4
13 peptidyl-glutamic acid carboxylation GO:0017187 9.54 BGLAP F2
14 cellular response to BMP stimulus GO:0071773 9.54 BMP2 COL2A1 RUNX2
15 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.52 BMP2 RUNX2
16 negative regulation of fibrinolysis GO:0051918 9.51 F2 SERPINE1
17 oxidative demethylation GO:0070989 9.49 CYP2C8 CYP3A4
18 proteoglycan metabolic process GO:0006029 9.48 BMP2 COL2A1
19 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.46 BMP2 RUNX2
20 lipid hydroxylation GO:0002933 9.43 CYP2C8 CYP3A4
21 bone resorption GO:0045453 9.43 ACP5 PTH TNFSF11
22 ossification GO:0001503 9.35 BGLAP BMP2 COL2A1 RUNX2 TNFSF11
23 skeletal system development GO:0001501 9.1 BGLAP BMP2 COL2A1 PTH RUNX2 TNFRSF11B
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 BMP2 PTH RUNX2 SERPINE1 TNFSF11 VEGFA

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 BMP2 TNFRSF11B TNFSF11 VEGFA
2 estrogen 16-alpha-hydroxylase activity GO:0101020 8.96 CYP2C8 CYP3A4
3 caffeine oxidase activity GO:0034875 8.62 CYP2C8 CYP3A4

Sources for Osteonecrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....